Choksi Laboratories Ltd

As of 02-Dec, Choksi Laboratories Ltd witnessed a decline in its share price, falling by 1.69% to close at ₹131.00. This downturn reflects a continuation of recent negative trends despite the stock’s impressive long-term performance relative to the broader market.

Choksi Laborator has experienced growth in net sales and operating income from Mar'21 to Mar'25, but its profitability metrics, including profit before and after tax, have fluctuated significantly. The company needs to focus on cost management and operational efficiency despite improved cash flow from operating activities.

As of 19-Nov, Choksi Laboratories Ltd's stock price is Rs 139.35, down 2.48%, with a significant decline of 14.56% over the past month. Despite strong long-term returns, recent performance has been poor, indicating a potential short-term correction amid decreased investor confidence.

As of 17-Nov, Choksi Laboratories Ltd's stock price is Rs 142.90, up 2.03% with a year-to-date increase of 90.36%. Despite recent gains, a significant drop in investor participation and underperformance against its sector indicate potential challenges in sustaining momentum.

Choksi Laborator has experienced steady growth in net sales and operating profit from March 2021 to March 2025, but its profitability has been volatile, with fluctuations in profit before and after tax. Total assets increased while total liabilities decreased, indicating improved financial stability despite challenges in managing costs.

As of 12-Nov, Choksi Laboratories Ltd is currently priced at Rs 135.00, reflecting a 9.05% increase, but it remains below key moving averages. Despite recent volatility, the stock has shown strong long-term performance with a year-to-date increase of 79.83%.

As of 11-Nov, Choksi Laboratories Ltd's stock price is Rs 123.80, down 9.1%, and has lost 17.41% over the last five days, underperforming the sector. Despite increased investor participation, the stock's volatility and recent decline indicate negative investor sentiment.

Choksi Laborator will announce its results on 14 November 2025.

As of 28-Oct, Choksi Laboratories Ltd's stock price has declined to 145.55, down 7.41%, and has underperformed its sector. The stock is trading below all key moving averages, indicating a bearish trend, with a significant drop in delivery volume and no additional context for its recent movement.

As of 20-Oct, Choksi Laboratories Ltd's stock price is declining at 157.05, down 3.71%, with a total drop of 7.02% over the last two days. Despite a strong year-to-date return of 109.20%, recent trends indicate a downturn and decreased investor participation, contrasting with the broader market's positive performance.

As of 15-Oct, Choksi Laboratories Ltd's stock price is Rs 166.40, down 7.4%, and has underperformed its sector significantly. Despite strong year-to-date and one-year returns, recent declines and negative performance indicators suggest ongoing challenges for the company.

As of October 13, 2025, Choksi Laborator is rated attractive but considered overvalued with high valuation ratios, including a PE of 85.25, despite strong stock performance, especially when compared to peers like Apollo Hospitals and Max Healthcare.

As of October 10, 2025, Choksi Laborator is considered very attractive and undervalued with a PE ratio of 82.47, a lower EV to EBITDA ratio of 13.39 compared to peers like Max Healthcare and Apollo Hospitals, and a remarkable year-to-date return of 136.58%.

As of October 10, 2025, Choksi Laborator is considered very attractive and undervalued with a PE ratio of 82.47, outperforming peers like Max Healthcare and Fortis Health, and achieving a remarkable 5-year return of 1516.01% compared to the Sensex's 103.66%.

As of October 10, 2025, Choksi Laborator is considered very attractive and undervalued with a PE Ratio of 82.47, lower than its peers, and has significantly outperformed the Sensex with a 1516.01% return over the past five years.